Annovis Bio (ANVS) said Monday it priced an underwritten public offering of about 5.3 million common shares and warrants to buy 5.3 million common shares at a combined price of $4 per share.
The company said the warrants will have an exercise price of $5 per share.
Total gross proceeds from the offering, which is expected to close on Tuesday, are expected to be $21 million, the company said.
Annovis Bio said it plans to use the net proceeds mainly for working capital and general corporate purposes, including the continued clinical development of its lead compound, Buntanetap.
The company's shares slipped past 30% in recent trading.
Price: 3.40, Change: -1.48, Percent Change: -30.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。